Thibault B.
- Country
- France
- Department
- oncology
Research Overview
- Comparison of mFOLFIRINOX Versus Platinum-Etoposide in First-Line Chemotherapy for Metastatic Grade 3 Gastroenteropancreatic Neuroendocrine Carcinoma
- Phase III Randomized Trial of mFOLFIRINOX Versus mFOLFOX in Adjuvant Treatment of High-Risk Stage III Colon Cancer
- Evaluation of Pembrolizumab Combined with XELOX and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer with High Immune Infiltrate
Data & Insights
Has run more than one trial at 54 of 157 partner sites.
Specializations
Gastrointestinal Oncology
This investigator specializes in the treatment of advanced colorectal cancers, with particular emphasis on high-risk stage III colon cancer. Their research focuses on innovative therapeutic approaches in the adjuvant setting.
- Colon Cancer Management
- Post-surgical Treatment Strategies
- Disease-Free Survival Assessment
The investigator evaluates combination chemotherapy regimens incorporating irinotecan and oxaliplatin for gastrointestinal malignancies.
Treatment Outcomes
The investigator's work centers on measuring and improving long-term survival outcomes in colorectal cancer patients, with specific attention to three-year disease-free survival metrics.
- Survival Rate Analysis
- Risk Assessment
- Treatment Response Monitoring
Their research encompasses the evaluation of therapeutic efficacy in high-risk patient populations following primary tumor resection.
Therapeutic Innovation
The investigator explores combination chemotherapy approaches in the adjuvant setting, focusing on optimizing treatment protocols for improved patient outcomes.
- Chemotherapy Combinations
- Adjuvant Treatment Protocols
- Risk-Adapted Therapy
Their work involves the assessment of novel treatment strategies for patients with aggressive forms of colon cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.